课题基金 / 基金详情

Integrative Cancer Scholars Training Grant

Integrative Cancer Scholars Training Grant
综合癌症学者培训补助金
批准号:
10680574
负责人:
Jennifer S Carew
金额:
$26.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
未结题
起止时间:
1983-09-01 至 2025-08-31

项目摘要

项目成果

Jennifer S Carew的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 我们的目标是招募,培训和发展癌症研究的下一代领导者。实现这一 目标,我们将实施综合癌症学者(ICS)计划,如本竞争性 延续我们长期的癌症生物学培训计划。ICS是一个创新的博士预科, 博士后研究员培训计划,采用配对导师团队的方法,以最大限度地发挥影响 癌症研究的意义。具体来说,学者选择一个基础科学导师和一个临床 从具有全国竞争力的基础科学家和医生科学家中挑选科学导师。从导师对, 学者从具有资金充足的合作研究项目的教师中选择一位“首席”导师, 广泛的癌症研究专业:基因组和表观遗传不稳定性,肿瘤微环境, 癌症预防和控制,发育治疗,癌症成像,肿瘤病毒和 免疫学、肿瘤进展和转移以及癌症疼痛。ICS是一个独特的程序, 旨在整合当前分子和临床癌症概念的培训活动。每一位学者都期待 在导师的指导下进行原创性的前沿研究,并参与临床 与他们所选择的医生导师进行交流。通过强制委员会确保每个学员的进步 会议和导师对年度评估。学者还参与职业发展, 国家网络的机会,包括在我们的癌症生物学研讨会系列主办思想领袖, 在教育研讨会上获得新的有针对性的技能,与肿瘤学家和 生物技术专家。此外,学者提供支持旅行,并提出他们的工作在一个国家 会议ICS与癌症生物学研究生跨学科计划有关,该计划提供 在癌症的病因,流行病学,预防,并通过具体的课程和补助金写作指令 专题讨论会介绍了博士前和博士后研究。博士后培养计划确保 每个受训者都能通过全面的培训,获得成熟的奖学金和能力, 进行独立的尖端研究。该计划旨在让每个学员接触到 癌症领域的当前思想,教授最先进的实验室技术,强调批判性思维 技能,介绍临床工作的现实世界方面,并完善他们的职业发展技能,特别是 在网络、通信和赠款/手稿准备方面。来自以下国家的博士后研究人员 参与导师的实验室有资格获得ICS的支持,学者通过 竞争过程。来自美国大学的支持,最先进的研究核心设施,以及 代表性不足的少数民族研究人员(UA是研究生院URM的所有研究I机构之首) 为培养癌症研究的未来领导者提供了丰富的环境。
英文摘要
Abstract Our goal is to recruit, train and develop the next generation of leaders in cancer research. To achieve this objective, we will implement the Integrative Cancer Scholars (ICS) program as described in this competitive renewal of our long-standing Cancer Biology Training Program. ICS is an innovative predoctoral and postdoctoral fellows training program that embraces a paired-mentor team approach to maximize the impact and significance of cancer research. Specifically, Scholars choose one basic science mentor and one clinical science mentor from among nationally competitive basic and physician scientists. From the mentor pair, the Scholar selects a `lead' mentor from among the faculty with well-funded collaborative research programs with a broad range of cancer research specialties: Genomic and Epigenetic Instability, Tumor Microenvironment, Cancer Prevention and Control, Developmental Therapeutics, Cancer Imaging, Tumor Viruses and Immunology, Tumor Progression and Metastasis, and Cancer Pain. ICS is a unique program with distinct training events designed to integrate current molecular and clinical cancer concepts. Each Scholar is expected to conduct original cutting-edge research under the guidance of the mentor-pair and to participate in clinical cases with their chosen physician mentor. Progress of each trainee is ensured through compulsory committee meetings and annual evaluations by the mentor-pair. Scholars also participate in career development and national networking opportunities, including hosting thought leaders in our Cancer Biology Seminar Series, acquiring new targeted skills in educational workshops, and community engagement with oncologists and biotechnology experts. Additionally, Scholars are provided support to travel and present their work at a national meeting. ICS is associated with the Cancer Biology Graduate Interdisciplinary Program which provides instruction in cancer causation, epidemiology, prevention, and grant writing through specific coursework and a symposium featuring presentations of pre- and postdoctoral research. The postdoctoral training plan ensures that each trainee navigates a path of comprehensive training, leading to a mature scholarship and ability to conduct independent, cutting-edge research. The program is designed to expose each trainee to the range of current thought in the cancer field, to teach state-of-the-art laboratory techniques, to emphasize critical thinking skills, to introduce real-world aspects of clinical work, and to refine their career-development skills, particularly in networking, communication and grant/manuscript preparation. Pre- and postdoctoral researchers from laboratories of the participating mentors are eligible for ICS support, and Scholars are selected through a competitive process. Support from the UA, state-of-the-art research core facilities, and opportunities for underrepresented-minority researchers (UA is top of all Research I institutions for URMs in graduate school) round out a rich environment for training the future leaders of cancer research.
期刊论文(69)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/0731-7085(89)80106-2
发表时间: 1989
期刊: Journal of pharmaceutical and biomedical analysis
影响因子: 3.4
作者: [Riley,CM, Monnot,EA, Stobaugh,JF, Slavik,M]
通讯作者: Slavik,M
Expression of beta-actin during progression of mouse skin tumors.
小鼠皮肤肿瘤进展过程中β-肌动蛋白的表达。
DOI: 10.1093/carcin/10.8.1439
发表时间: 1989
期刊: Carcinogenesis
影响因子: 4.7
作者: [Ostrowski,LE, Krieg,P, Finch,J, Cress,AE, Nagle,RB, Bowden,GT]
通讯作者: Bowden,GT
Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis.
EVI1基因在慢性粒细胞白血病急变期的表达。
DOI: --
发表时间: 1993
期刊: Leukemia
影响因子: 11.4
作者: [Russell,M, Thompson,F, Spier,C, Taetle,R]
通讯作者: Taetle,R
B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro.
B7-1 可在体内增强对分泌白细胞介素 2 的肿瘤疫苗的反应,但无法在体外诱导幼稚细胞的反应。
DOI: 10.1089/hum.1995.6.10-1299
发表时间: 1995
期刊: Human gene therapy
影响因子: 4.2
作者: [Salvadori,S, Gansbacher,B, Wernick,I, Tirelli,S, Zier,K]
通讯作者: Zier,K
共 52 条
    Targeting Lysosomal Vulnerabilities in Renal Pathogenesis
    • 批准号:
      10570295
    • 项目类别:
    • 资助金额:
      $47.12万
    • 财政年份:
      2022
    • 负责人:
      Jennifer S Carew
    • 依托单位:
    Development of lysosome targeted therapeutics
    • 批准号:
      10482643
    • 项目类别:
    • 资助金额:
      $25.83万
    • 财政年份:
      2022
    • 负责人:
      Jennifer S Carew
    • 依托单位:
    Targeting NEDD8-Mediated Protein Turnover in AML
    • 批准号:
      8632457
    • 项目类别:
    • 资助金额:
      $30.88万
    • 财政年份:
      2014
    • 负责人:
      Jennifer S Carew
    • 依托单位:
    Targeting NEDD8-Mediated Protein Turnover in AML
    • 批准号:
      8845524
    • 项目类别:
    • 资助金额:
      $8.83万
    • 财政年份:
      2014
    • 负责人:
      Jennifer S Carew
    • 依托单位:
    海外基金